Page 10 - Rna News Today

The UK launches groundbreaking Mobilize trial using mRNA-4359 for melanoma and lung cancer, tapping into the patient's immune system for targeted and less toxic cancer treatment.

At the heart of the human microbiome, a team of researchers from Stanford University has recently made a rather surprising discovery: the presence of a class of unprecedented...

Learn about a novel non-viral gene transfer system which could transform cell and gene therapy workflows

Alternating Hemiplegia of Childhood, or AHC, could see a new treatment thanks to a team of neurologists at Boston Children's Hospital.

Discover why working as a certified registered nurse anesthetist is ranked among the top and highest-paying jobs in healthcare for 2024.

Swiss contract drug manufacturer Lonza has partnered with Oxford Nanopore to enhance the analysis of mRNA products.

The global messenger ribonucleic acid (mRNA) vaccine market currently consists entirely of vaccines for COVID-19.

The U.S. government, the mainstream media, and so-called experts long downplayed the possibility of a link between heart inflammation and COVID-19 vaccines. Elements of the medical establishment and social media companies worked to shut up those who dared to press the issue. Health officials a...

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) CEO Sarah Boyce sold 5,092 shares of the company’s stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $10.13, for a total value of $51,581.96. Following the completion of the transaction, the chief executive officer now owns 44,008 shares […]

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) CEO Sarah Boyce sold 5,092 shares of the business’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $10.13, for a total value of $51,581.96. Following the sale, the chief executive officer now owns 44,008 shares of the company’s […]